ArticleCancers2019
SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Regulatory mechanism of the RNF168-SCCA1-MYH9 signaling axis in the response of ulcerative colitis.Journal of gastroenterology · 2026Article
- 1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.International journal of molecular sciences · 2026Article
- When the Liver Flares: Inflammatory and Immunometabolic Mechanisms Driving the Transition from MASLD to MASH.Inflammation · 2026Review
- Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus-Associated Hepatocyte Remodeling and Hepatocellular Carcinoma.Immunity, inflammation and disease · 2025Review
- Hypoxia-inducible factor-1 as targets for neuroprotection : from ferroptosis to Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Inhibition of Protease-Activated Receptor-2 Activation in Parkinson's Disease Using 1-Piperidin Propionic Acid.Biomedicines · 2024Article
- Review
- Review
- Editorial: Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies.Frontiers in immunology · 2024Article
- SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer.Cell reports · 2023Article
- Article
- Review
- SerpinB3 administration protects liver against ischemia-reperfusion injury.European journal of histochemistry : EJH · 2022Article
- Semisolid Wet Sol-Gel Silica/Hydroxypropyl Methyl Cellulose Formulation for Slow Release of Serpin B3 Promotes Wound Healing In Vivo.Pharmaceutics · 2022Article
- Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.The Journal of pathology · 2022Article
- SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.Frontiers in immunology · 2022Article
- Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy.Radiation oncology (London, England) · 2021Article
- Review
- Engineered EVs for Oxidative Stress Protection.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 2 countries.
Stefania CannitoDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.ORCID 0000-0001-9883-6882
Beatrice FogliaDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.ORCID 0000-0001-7973-9681
Gianmarco VillanoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.
Cristian TuratoVeneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0001-7086-0792
Teresa C DelgadoLiver Disease and Metabolism Laboratory, CIC bioGUNE, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (Ciberehd), Technology Park of Bizkaia, 48160 Derio, Bizkaia, Spain.ORCID 0000-0001-9204-581X
Elisabetta MorelloDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.
Fabrizio PinDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.
Erica NovoDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.
Lucia NapioneDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Torino, Italy.ORCID 0000-0003-2648-1466
Santina QuartaDepartment of Medicine, University of Padova, 35128 Padova, Italy.ORCID 0000-0002-9348-1485
Mariagrazia RuvolettoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.ORCID 0000-0001-5507-6422
Silvano FasolatoDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.ORCID 0000-0002-5730-2267
Giacomo ZanusHepatobiliary Surgery, University of Padova, 35128 Padova, Italy.
Sebastiano ColombattoDepartment of Oncology, University of Torino, 10125 Torino, Italy.
Fernando Lopitz-OtsoaLiver Disease and Metabolism Laboratory, CIC bioGUNE, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (Ciberehd), Technology Park of Bizkaia, 48160 Derio, Bizkaia, Spain.
David Fernández-RamosLiver Disease and Metabolism Laboratory, CIC bioGUNE, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (Ciberehd), Technology Park of Bizkaia, 48160 Derio, Bizkaia, Spain.
Federico BussolinoLaboratory of Vascular Oncology, Candiolo Cancer Institute-IRCCS, 10060 Candiolo, Italy.
Salvatore SuttiDepartment of Health Sciences and Interdisciplinary Research Center for Autoimmune Diseases, University Amedeo Avogadro of East Piedmont, 28100 Novara, Italy.ORCID 0000-0002-0192-8199
Emanuele AlbanoDepartment of Health Sciences and Interdisciplinary Research Center for Autoimmune Diseases, University Amedeo Avogadro of East Piedmont, 28100 Novara, Italy.ORCID 0000-0003-4738-7049
Maria Luz Martínez-ChantarLiver Disease and Metabolism Laboratory, CIC bioGUNE, Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (Ciberehd), Technology Park of Bizkaia, 48160 Derio, Bizkaia, Spain.
Patrizia PontissoDepartment of Medicine, University of Padova, 35128 Padova, Italy.
Maurizio ParolaDepartment of Clinical and Biological Sciences, Unit of Experimental Medicine & Clinical Pathology, University of Torino, 10125 Torino, Italy.ORCID 0000-0001-7720-5141
University of Turin · ITUniversity of Padua · ITCIC bioGUNE · ESUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITCandiolo Cancer Institute · ITIstituto Oncologico Veneto · ITPolitecnico di Torino · IT
Funding
Associazione Italiana per la Ricerca sul Cancro IG 2017 Id.20361EITB Maratoia BIO15/CA/014Gobierno 779 Vasco-Departamento de Salud 2013111114MINECO SEV-2016-0644MIUR, Rome: 776 PRIN Project 2006067527SAF2017-87301-R SAF2017-87301-RUniversity of Padova CPDA110795
Abstract
backgroundSerpinB3 (SB3) is a hypoxia and hypoxia-inducible factor (HIF)-2α-dependent cysteine-protease inhibitor up-regulated in hepatocellular carcinoma (HCC), released by cancer cells and able to stimulate proliferation and epithelial-to-mesenchymal-transition. Methods
Indexed as
HCChypoxiahypoxia inducible factors HIF-1α and HIF-2αNEDD8NEDDylationSerpinB3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.